PA’s initial brief was to turn the concept into a prototype for use in preclinical testing to determine whether the physical characteristics of the product in vitro lent themselves to a safe and effective delivery system.
PA also advised on clinical and regulatory aspects of the clinical development programme.
From significant experience of running product development programmes involving multiple suppliers, PA recognised the need to establish a formal project team structure comprising function specific workstreams, whose activities would be monitored by a project office and governed by a project steering committee.
This structure and PA’s rapid prototyping ability were major contributory factors to ensuring that the project team met the objectives of taking the concept to phase-one clinical trials within 16 months (including the successful submission of an IND application), and to phase-two trials within 24 months.
To find out more about our drug delivery capability, please contact us now.